Ligand Pharmaceuticals has agreed to buy the struggling Metabasis Therapeutics for $3.2 million in cash.
Author: Global Cancer Consortium
On 10/19/09, BioElectronics (OTC: BIEL.PK) announced the initial results from the pilot section of its ongoing acetaminophen comparison study.
OneMedPlace recently interviewed CEO Jeffrey Davis about the Dallas-based company’s pipeline.
BDSI focuses on the niche market of pain management and supportive cancer care.
Onyx Pharmaceuticals has agreed to purchase private biotechnology company Proteolix for $276 million in cash.
Peregrine Pharmaceuticals reported positive Phase II data in a clinical trial of bavituximab in patients with a deadly form of lung cancer.
Inovio Biomedical (AMEX: INO) is developing a robust pre-clinical and early clinical stage pipeline of innovative DNA-based vaccines and therapeutics that target cancer, influenza, and other infectious diseases (e.g. HIV) based on its SynCon DNA vaccine construct and electroporation DNA delivery technology platforms.
On 9/22/09, BioSante and Cell Genesys (NASDAQ: CEGE) announced that they have determined the final exchange ratio will be 0.1828 in connection with the previously announced merger between the companies.